Navigation Links
Antibiotic treatment targets difficult asthma
Date:12/17/2007

Hunter researchers have shown that a commonly available antibiotic can improve the quality of life of patients with difficult asthma, and may also generate significant health care savings.

Results of a study published in the American Journal of Respiratory and Critical Care Medicine, a top international journal, indicate that macrolide antibiotics could prove a successful therapy in conjunction with current asthma treatment.

The study was conducted by researchers from the University of Newcastle and Hunter New England Health in collaboration with the Hunter Medical Research Institute (HMRI) Viruses, Infections/Immunity,Vaccines and Asthma (VIVA) Research Program.

Current asthma medication is focused on treating a particular cell, called an eosinophil. Increased levels of eosinophils are thought to be responsible for inflammation of the airways. However, almost half of people with asthma symptoms have normal levels of eosinophils.

In a previous study we have shown that an inflammatory cell called the neutrophil is increased in some asthma patients and that treatments are needed to combat other types of inflammation in people with asthma, said Dr Jodie Simpson from the University of Newcastles Priority Research Centre for Asthma and Respiratory Diseases. Researchers studied 45 people who had poor asthma control and were taking high daily maintenance doses of inhaled corticosteroids. In addition to their regular asthma therapy, participants received a macrolide antibiotic (called klacid) or placebo medication for eight weeks.

In this study we have shown that treatment with a macrolide antibiotic for eight weeks significantly reduced inflammation in the airways and improved quality of life in patients with difficult asthma, said Dr Simpson.

Patients with non-eosinophilic asthma particularly benefited from this treatment and this group of patients had the biggest response to the treatment. This treatment significantly reduced the number of neutrophils in the airway.

This finding is significant because 5 to 10 per cent of asthma cases are considered difficult and these account for 50 per cent of asthma treatment and health care costs.


'/>"/>

Contact: Lauren Eyles
61-249-214-841
Research Australia
Source:Eurekalert

Related medicine news :

1. New antibiotic drug combo to speed up treatment of tuberculosis
2. Newer Antibiotic Speeds TB Healing
3. Antibiotics Not Always Best Bet for Battling Childhood Ear Infections
4. Antibiotic Shows Promise as Stroke Treatment
5. Ear infection superbug discovered to be resistant to all pediatric antibiotics
6. Antibiotics May Not Help Mens Chronic Pelvic Pain: Harvard Doctors Discuss Alternatives
7. Study Shows Antibiotic Harms ALS Patients
8. Dragon Sells EPO Business; Focus on Antibiotic Core Business
9. Drug Combo With Antibiotic May Slow MS Progression
10. New treatment effective in counteracting cocaine-induced symptoms
11. New treatment boosts muscle function in myasthenia gravis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who ... now take advantage of a cosmetic procedure known as Carbon Dioxide (C02) ... the appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, skin ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Halfway through ... Medicine has provided preventative dental services to more than 15,900 children 5 years old ... 5 LA pledged $38 million over a span of five years to Western University ...
(Date:12/2/2016)... ... 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host the ... the 2016 MPN Heroes—eight individuals who have made a difference in the field of ... standard of care, demonstrating leadership within the MPN community and/or a commitment to individual ...
(Date:12/2/2016)... ... ... Advanced Inc., a leading provider of travel therapy and travel nursing across ... Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as Vice ... leadership experience to Advanced Inc. He began his career in finance at Ernst & ...
(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... Dec. 3, 2016 Johnson & Weaver, LLP announces ... purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ... October 31, 2016 (the "Class Period"). Zimmer Biomet ... markets orthopaedic reconstructive products, such as knee and hip reconstructive ... , , ...
(Date:12/4/2016)... highly innovative, personalized cell-based treatment for a high-risk form of the most ... Children,s Hospital of Philadelphia today reported new results ... The physician-scientists presented findings at the annual meeting of the ... Continue Reading ... ...
(Date:12/2/2016)... -- bioLytical Laboratories, un líder mundial en test rápidos de enfermedades ... Test , a los miembros de la Kenya Pharmaceutical Association. ... ... HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la Clinton Health ...
Breaking Medicine Technology: